Method for treating blood, blood products and organs

1. A method for treating blood, a blood product and/or an organ in vitro or ex vivo, wherein the method comprises removing the blood, blood product and/or organ from the human or animal body and removing and/or detoxifying amyloid-beta oligomers from the removed blood, blood product and/or organ, and wherein the method comprises contacting the blood, blood product and/or organ with one or more compounds which comprise the compound rprtrlrthqnr (DB 4:SEQ ID NO:1).

2. The method of claim 1 , wherein the method further comprises examining the blood, blood product and/or organ for the presence of amyloid-beta oligomers prior to removing the blood, blood product and/or organ from the human or animal body.

3. The method of claim 1 , wherein the one or more compounds are arranged as capture molecules on a support, via which a sample containing the blood, blood product and/or organ is passed.

4. The method of claim 3 , wherein the capture molecules are fixed onto beads.

5. The method of claim 3 , wherein the capture molecules are immobilized on nanomagnets.

6. The method of claim 3 , wherein the capture molecules are arranged in a dialysis system.

7. The method of claim 3 , wherein the support for the capture molecules is made of a biocompatible material.

8. The method of claim 3 , wherein the support for the capture molecules is selected from one or more of membranes, filters, filter sponges, beads, rods, cords, column, hollow fibers.

9. The method of claim 1 , wherein a kit is used for a selective quantification of A-beta aggregates and/or for treating (in vitro) blood, a blood product and/or an organ, the kit comprising one or more of:

a substrate made of glass which is coated with a hydrophobic material;

a standard;

a capture molecule;

a probe;

a substrate with capture molecule;

one or more solutions;

a buffer.

10. The method of claim 1 , wherein the one or more compounds are passed as capture molecules ex vivo over and/or through an organ.

11. The method of claim 1 , wherein the method comprises removing amyloid-beta oligomers from blood, a blood product and/or an organ.

12. The method of claim 11 , wherein Alzheimer's disease is treated.

13. The method of claim 1 , wherein the method comprises detoxifying amyloid-beta oligomers present in blood, a blood product and/or an organ.

14. The method of claim 13 , wherein Alzheimer's disease is treated.

15. The method of claim 1 , wherein the one or more compounds further comprise one or more hybrid compounds of formula A-B, where A is an aminopyrazole or a derivative thereof, and B is a peptide selected from SEQ ID NO:1, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76,

and A and B are covalently bonded to one another directly or by a linker.